Findings set the stage for further investigation of hSFRP2 mAb as a targeted therapy for triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows ...

Leading institutional investors commit $240 million through private investment in public equity (PIPE) led by Perceptive Advisors and RA Capital - - Freenome stockholders ...

Leading institutional investors commit $240 million through private investment in public equity (PIPE) led by Perceptive Advisors and RA Capital – – Freenome stockholders, PCSC shareholders and PIPE ...

As new technology capable of detecting dozens of early-stage cancer types with a single blood test hits the market, support ...